<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05003232</url>
  </required_header>
  <id_info>
    <org_study_id>20210618</org_study_id>
    <nct_id>NCT05003232</nct_id>
  </id_info>
  <brief_title>NIRS Directed Optimal Cerebral Perfusion Pressure on the Outcome of Aneurysmal Subarachnoid Hemorrhage Patients</brief_title>
  <official_title>NIRS Directed Optimal Cerebral Perfusion Pressure on the Outcome of Aneurysmal Subarachnoid Hemorrhage Patients: A Multicenter, Single-blinded, Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives: To investigate the impact of NIRS directed optimal cerebral perfusion pressure on&#xD;
      the outcome of aSAH patients.&#xD;
&#xD;
      Study design: A multicenter, single-blinded, randomized controlled trial. Setting:&#xD;
      Departments of critical care medicine of tertiary hospitals in China. Patients: 150 aSAH&#xD;
      patients (≥ 18 years old) who admitted to ICU (predicted ICU duration time ≥ 24 hours)&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Patients with aSAH will be randomly divided into the control group and the intervention&#xD;
      group. The control group will follow the SAH guidelines. The intervention group will be given&#xD;
      continuous NIRS and invasive blood pressure monitoring at same time. The correlation curve&#xD;
      between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood&#xD;
      pressure will be obtained through continuous monitoring. According to the correlation curve,&#xD;
      the optimal blood pressure will be determined which provides the optimal CPP. Then the goal&#xD;
      of blood pressure (within 5 mmHg of CPPopt) will be maintained as the target of blood&#xD;
      pressure management for the intervention group during ICU stay.&#xD;
&#xD;
      Primary outcome: Neurological prognosis (GCS score，GOS score, and NIHSS score when discharge&#xD;
      from ICU; GOS score at 6 months), etc.&#xD;
&#xD;
      Predicted duration of the study: 2 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological prognosis at the discharge from ICU and at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>GOS score at 6 months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Optimal Cerebral Perfusion Pressure on the Outcome of aSAH Patients</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal MAP group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Near-infrared spectroscopy (NIRS) and ICM+</intervention_name>
    <description>The intervention group will be given continuous NIRS and invasive blood pressure monitoring at same time. The correlation curve between the brain oxygenation index or the brain hemoglobin index (ORI/THx) and the blood pressure will be obtained through continuous monitoring. According to the correlation curve, the optimal blood pressure will be determined which provides the optimal CPP. Then the goal of blood pressure (within 5 mmHg of CPPopt) will be maintained as the target of blood pressure management for the intervention group during ICU stay.</description>
    <arm_group_label>Optimal MAP group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years;&#xD;
&#xD;
          -  Admitted to ICU because of aSAH.&#xD;
&#xD;
          -  Predicted to stay in ICU ≥ 24 hours&#xD;
&#xD;
          -  Provide written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to perform NIRS monitoring because of anatomic factors;&#xD;
&#xD;
          -  Patients with severe organ failure;&#xD;
&#xD;
          -  In addition to aneurysmal subarachnoid hemorrhage, there are other serious&#xD;
             intracranial diseases (intracranial infection, cerebral hemorrhage, cerebral&#xD;
             infarction, brain trauma, other patients after intracranial surgery);&#xD;
&#xD;
          -  Patients with carotid plaque or thrombus;&#xD;
&#xD;
          -  Patients with severe intracranial pneumatosis after craniotomy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>August 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

